phthalazinol
RN given refers to parent cpd; do not confuse with phthalazinol: 62054-23-3; thromboxane A2 antagonist
Also Known As:
EG 626; EG-266
Networked: 9
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Dementia (Dementias)
|
2. | Atherosclerosis
01/01/1978
- " Atherosclerosis was produced in rabbits by feeding 1% cholesterol pellets for 15 weeks to 35 male rabbits divided into two equal groups--the placebo control and phthalazinol group--with a comparable serum cholesterol level. " 01/01/1978
- " In light of the pharmacological properties of phthalazinol, the possible role of thromboxane A2 released from platelets adhered and aggregated on atheromatous plaques, in the progression of atherosclerosis is worthy of continued investigation." 12/01/1979
- " Phthalazinol (EG 626), a thromboxane A2 antagonist and cyclic AMP phosphodiesterase inhibitor, has been shown to prevent the atherosclerosis induced in cholesterol fed rabbits. " 01/01/1976
- " Various smooth muscle relaxants, such as ATP, pyridinol carbamate (ATP synthesis-enhancing substance), cycli-AMP, dibutyryl cycli-AMP, phthalazinol (cyclic-AMP phosphodiesterase inhibitor), iproveratril (calcium entry-inhibiting substance), colchicine, and vinblastine, with their different modes of action, commonly inhibited phagocytic activities, a finding that suggests a significant role for contractile protein in the permeability problem of atherogenesis. "
|
3. | Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
|
4. | Atherosclerotic Plaque (Atheroma)
|
5. | Thrombosis (Thrombus)
|
|
Related Drugs and Biologics